BBI Solutions

73 Ty Glas Avenue
Cardiff,  CF14 5DX

United Kingdom
  • Booth: 1539


BBI Solutions is a leading supplier of biological raw materials and finished test platforms to the IVD market. We have grown from a small specialist company to a global business with manufacturing sites spanning three continents. Our range of raw materials includes antigens, antibodies, enzymes and serum and plasma products. We manufacture world renowned labels for lateral flow and ELISA, including gold nanoparticles, horseradish peroxidase and alkaline phosphatase.

 Press Releases

  • The BBI Group, partner to the world’s leading diagnostic and healthcare organisations, has entered into a definitive agreement to acquire the Maine Biotechnology Services, Inc. (MBS) located in Portland, Maine (USA).

    The acquisition of MBS will expand BBI’s portfolio during a period of expansion and growth. The company provides a range of products to the diagnostic, healthcare, research food sectors globally. MBS will add antibody development to its capability and product range.

    Lyn Rees, CEO of the BBI Group, said: “The acquisition of MBS perfectly complements our current product portfolio and coincides with our commercial team expansion, giving us important new technology and products.

    “We are very excited about future growth potential for the business.  We expect to develop new products for our customers and directly for BBI and I am hugely excited by the opportunity to increase the services we provide for our customers. This will in turn underpin our business for many years to come.”

    Dr Joseph Chandler, Founder and President of MBS, said: “The BBI Group was aware of our reputation in the market for high quality antibody products services. They currently have no capacity for antibody development and manufacture and, with a waiting customer base for this, MBS is a logical addition to their business. They are on an ambitious growth plan and I know that MBS will be a key part of their future plans.”

    The completion of the acquisition took place by the end of June.

  • Novarum DX is set to showcase how to read and share the results of diagnostic tests using a smartphone, during the week of the American Association for Clinical Chemistry (AACC) annual meeting in San Diego.

    The free breakfast seminar is not part of the official AACC programme, but it complements the conference theme of innovative clinical lab technologies, whilst providing professionals from the global medical industry with the opportunity to learn more about technologies for next generation diagnostics.     

    Novarum, acquired by BBI Group in October 2016, will showcase their unique smartphone reader technology, which enables the results of diagnostic tests to be accurately read at the point of care. The intuitive mobile app allows patients to share test results securely, with healthcare professionals and minimal end-user training.

    Dr. Niall McLaren, Business Development Manager at Novarum, commented:

    “We’re delighted to be holding this breakfast seminar on technologies for next generation diagnostics. Novarum’s custom apps are used by established diagnostic companies and we also work with smaller, more nimble specialists to develop original approaches to monitor infectious disease, toxicology and auto-immune disease.

    Novarum’s technology has the potential to deliver a step-change in traditional diagnostic processes using a smartphone, and we look forward to welcoming delegates to an informative session, which will also deliver great networking opportunities.”

    The seminar will also provide delegates with the opportunity to learn more about BBI Solutions’ innovative Morffi Signal Enhancement Technology. Developed by BBI scientists in-house, the novel conjugation technology improves assay performance and has proven to increase the sensitivity, as well as achieve a faster time to result in lateral flow assays.

    Places are limited and booked on a first-come, first-served basis. To book, or for more information, visit: . If you are attending AACC, there is an opportunity to meet representatives from Novarum and BBI Solutions at stand no. 1539.

  • BBI Solutions (BBI), recent winner of a Diagnostics Marketing Association Award for its Morffi™ signal enhancement technology, is gearing up to attend the 69th AACC Annual Scientific Meeting & Clinical Lab Expo next month. This year’s event is being held in sunny San Diego, California, and will provide delegates with the perfect backdrop to discover how Morffi technology can improve the specificity and time to result for immunoassays. A team of BBI Solutions’ technical experts and commercial managers will be on hand on booth #1539 to discuss this novel technology, as well as the company’s biological raw materials, capabilities and expertise in lateral flow assay development and manufacturing.

    BBI Solutions Managing Director, Liam Taylor, explained: “We export to more than 60 countries – representing over 92 % of our sales revenue – and so AACC is an important event for us, offering a rare chance to see many of our overseas customers in one place. The US market is a key area of focus at this time, and we have appointed several US-based personnel to better serve this expanding customer base. This investment is being complemented by the establishment of BBI China as a legal entity, further expanding our global footprint.”

    Visitors to the booth will also be able to explore BBI’s recently extended antibody portfolio, which now includes several new cancer, fertility, cardiac and inflammation markers in response to market demands. This product range will soon be further enhanced by the imminent acquisition of Maine Biotechnology Services, a Portland-based company with over 25 years of experience in antibody development, which will allow BBI to offer additional products and tried and trusted custom development services.

    Visit BBI Solutions on booth #1539 to learn more about its products and services, or pre-book a meeting with our team.

 Additional Info

Countries of Interest:
Austria, Belgium, Canada, China, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea (South), Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, United Kingdom, United States